Feedback / Questions
SIRPant-M (SI-101) - SIRPant Immunotherap
https://www.globenewswire.com/news-release/2024/03/12/2844459/0/en/SIRPant-Immunotherapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-Evaluating-SIRPant-M-in-Patients-with-Relapsed-Refractory-Non-Hodgkin-Lymphoma.html
Mar 12, 2024
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next